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BRIDGE: An Open-Label Phase II Trial Evaluating the Safety
of Bevacizumab  Carboplatin/Paclitaxel as First-Line
Treatment for Patients with Advanced, Previously
Untreated, Squamous Non-small Cell Lung Cancer
John D. Hainsworth, MD,* Liang Fang, PhD,† Jane E. Huang, MD,† David Karlin, MD,†
Kenneth Russell, MD,‡ Leonardo Faoro, MD,† and Christopher Azzoli, MD§
Background: Patients with predominantly squamous non-small cell
lung cancer (NSCLC) have been generally excluded from studies of
bevacizumab treatment, because squamous histology was identified
as a possible risk factor for severe (grade 3) pulmonary hemor-
rhage (PH) in a phase II study. BRIDGE was designed to determine
whether delaying initiation of bevacizumab treatment and selecting
patients without baseline risk factors for PH would lower the
incidence of severe PH among patients with squamous NSCLC.
Methods: Patients in this open-label, single-arm study were treated
with carboplatin/paclitaxel for two cycles, followed by carboplatin/
paclitaxel and bevacizumab in cycles 3 to 6, followed by bevaci-
zumab until progression or unacceptable toxicity. Eligible patients
had stage IIIb, stage IV, or recurrent squamous NSCLC. The
primary end point was incidence of grade 3 PH.
Results: Grade3 PH occurred in 1 of 31 patients who received1
dose of bevacizumab: estimated incidence was 3.2% (90% confi-
dence interval 0.3–13.5%). The patient experienced grade 3 PH,
discontinued from the study, then experienced grade 4 PH 10 days
later, and died of progressive disease. No other serious bleeding
events occurred. Nine patients (29.0%) experienced grade 3 adverse
events, including five with hypertension; five patients experienced
grade 4 adverse events (dyspnea, PH, basal ganglia infarction,
cerebral ischemia, and pain). Median progression-free survival was
6.2 months (95% confidence interval 5.32–7.62 months).
Conclusions: The incidence of grade 3 PH was 3.2% (one
patient). No new safety signals were identified. Although the rate of
PH was low, the number of patients in this study was also low.
Treatment of squamous NSCLC with bevacizumab should be con-
sidered experimental.
Key Words: Squamous, Non-small cell lung cancer, Bevacizumab,
Pulmonary hemorrhage, Delayed initiation.
(J Thorac Oncol. 2011;6: 109–114)
Lung cancer is the leading cause of cancer death in the UnitedStates, with 219,440 new cases, and 159,390 deaths esti-
mated to have occurred in 2009.1 Approximately 85% of lung
cancers are non-small cell lung cancers (NSCLCs), of which
approximately one third have squamous histology. Squamous
cell carcinomas tend to arise in the proximal large bronchi,
potentially increasing the risk of pulmonary hemorrhage (PH) in
patients with squamous tumors.
Bevacizumab (Avastin, Genentech Inc., South San
Francisco, CA) is a recombinant, humanized monoclonal
antibody directed against vascular endothelial growth factor,
a key factor in tumor-associated angiogenesis. A randomized,
phase II trial (AVF0757g) of carboplatin/paclitaxel (CP) 
bevacizumab for patients with advanced NSCLC initially
showed that bevacizumab was effective for treatment. How-
ever, among 13 patients with squamous NSCLC, there were
4 (31%) cases of severe PH.2–4 Consequently, patients with
squamous NSCLC were excluded from the seminal phase
II/III NSCLC trial conducted by the Eastern Cooperative
Oncology Group (ECOG; Study E4599)5 and have been
generally excluded from the subsequent studies of bevaci-
zumab for the treatment of NSCLC.5,6 A case-control evalu-
ation of clinical and radiographic factors associated with
these events concluded that squamous cell histology and
bevacizumab treatment were the principal risk factors for
severe PH.4
Because in the AVF0757g trial the first dose of bev-
acizumab and chemotherapy was administered on day 1 of
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each treatment cycle, and because two of the four PH events
in AVF0757g occurred early during the course of treatment
(13 and 12 days after the first infusion),2 it was hypothesized
that delaying bevacizumab administration until after initial
chemotherapy cycles might permit time for cytoreduction and
epithelial healing, thereby protecting against occurrence of
PH during early treatment. The AVF3744g pilot study
(BRIDGE) described in this report was designed to explore
whether such delay in initiation of bevacizumab treatment
combined with selecting subjects without baseline risk factors
for PH would result in a lower incidence of severe PH than
was observed in the prior AVF0757g trial.
PATIENTS AND METHODS
Eligibility Criteria
Patients were eligible for this study if they had histolog-
ically or cytologically confirmed stage IIIB (with pleural effu-
sion), stage IV, or recurrent predominantly squamous NSCLC;
had measurable or evaluable disease; were 18 years or older; and
had signed informed consent. An August 6, 2007 study amend-
ment permitted enrollment of patients with previously treated
brain metastases (formerly excluded). The 2007 study amend-
ment also permitted the enrollment of patients with ECOG
performance status (PS) 2 (formerly only ECOG PS 0–1 were
permitted). However, only patients whose ECOG PS status was
0 or 1 by cycle 3 (i.e., after two cycles of chemotherapy) were
permitted to receive any bevacizumab in this study.
Exclusion criteria included prior chemotherapy for met-
astatic disease; adjuvant or combined modality therapy within
6 months before study entry; extrathoracic metastases as the
only sites of disease; untreated brain metastases; cavitation in
intrathoracic lesions; gross hemoptysis within 3 months be-
fore study entry; major surgical procedure, open biopsy, or
significant traumatic injury within 28 days before study;
urinary protein creatinine ratio 1.0; and other general and
laboratory-based exclusions. The following conditions were
also reasons for exclusion: history of unstable angina; grade
2 congestive heart failure; abdominal fistula; gastrointesti-
nal perforation; intraabdominal abscess; myocardial infarc-
tion; stroke; active symptomatic peripheral vascular disease
within 6 months before study; history of significant vascular
disease; evidence of bleeding diathesis or coagulopathy; and
serious nonhealing wound, ulcer, or bone fracture. After a
study amendment (June 12, 2006), the presence of tumor
cavitation before initiation of bevacizumab therapy was
added as an exclusion criterion based on a reanalysis of data
from prior studies (bevacizumab; Genentech Inc.),3 which
indicated that cavitation might be associated with PH. After a
second study amendment (August 6, 2007), patients with
baseline evidence (radiologic or investigator determined) of
tumor impingement or extension into the lumen of a major
blood vessel (e.g., pulmonary artery or superior vena cava),
or invading vascular structures, were also excluded.
Study Design
This was an open-label, single-arm, multicenter pilot
study to evaluate the safety and efficacy of first-line CP plus
bevacizumab (see study schematic, Figure 1). The study was
divided into three treatment intervals: CP alone (cycles 1 and
2), CP plus bevacizumab (cycles 3–6), and bevacizumab
alone (cycles 7 and beyond).
The primary objective of BRIDGE was to estimate the
rate of grade 3 PH associated with delayed administration of
bevacizumab for the treatment of patients with locally advanced,
recurrent, or metastatic squamous NSCLC. Secondary objec-
tives were to describe the incidence of select adverse events
(AEs) in patients who received bevacizumab treatment through
the safety follow-up period and to estimate progression-free
survival (PFS) among patients who completed two cycles of
chemotherapy and received bevacizumab. Baseline and post-
baseline factors, including radiographic factors, were assessed
for correlations with the risk of severe PH.
Enrollment of 40 subjects was planned, at approxi-
mately 25 centers in the United States, to achieve 30 bevaci-
zumab-treated subjects. Study safety was monitored through
review of AEs by the sponsor and a Scientific Advisory
Board. Enrollment and bevacizumab treatment were to be
stopped if three or more Grade 3 PH events were observed
among 30 bevacizumab-treated patients (estimated incidence
of approximately 10%) on-study or up to 60 days after
discontinuing bevacizumab. Stopping rules, if implemented,
would halt enrollment and bevacizumab treatment (for sub-
jects on study) and would initiate a thorough reexamination
of safety.
Although concurrent full-dose anticoagulation with as-
pirin (325 mg) or full-dose warfarin (or its equivalent) was
not permitted, low-dose (1–2 mg) warfarin was permitted for
prophylaxis of intravascular catheters. Subcutaneous (pro-
phylactic) heparin was permitted.
Data Collection
Tumor assessments were conducted on computed to-
mography (CT) or magnetic resonance imaging scans of the
chest, abdomen, and other known or suspected sites of dis-
ease and were evaluated according to institutional standards.
In addition to individual institutional review, imaging (CT or
magnetic resonance imaging chest scans) assessment was
conducted by an independent review facility (RadPharm Inc.,
Princeton, NJ). ECOG PS assessment was conducted at each
treatment cycle.
Protocol-specified select AEs to be collected included
the following: any grade PH, non-PH, or gastrointestinal
FIGURE 1. Schematic of the study design for BRIDGE.
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perforation, grade 2 arterial thromboembolic events, grade
2 left ventricular systolic dysfunction, grade 3 protein-
uria, grade 3 hypertension, any serious AE, and any AE
leading to study treatment discontinuation. The study was
amended (June 12, 2006) to provide additional specific in-
formation on reversible posterior leukoencephalopathy syn-
drome and hypertensive encephalopathy.
Treatment Discontinuation and Modification
Criteria
Bevacizumab treatment was to be discontinued in the
event of any grade PH, venous thrombosis, arterial thromboem-
bolic event, and wound dehiscence; grade 2 gastrointestinal
perforation; grade 3 non-PH; grade 4 hypertension, protein-
uria, left ventricular systolic dysfunction, or other events con-
sidered related to bevacizumab for up to 6 weeks. Patients were
discontinued from the study before receiving first dose of bev-
acizumab (cycle 3) for any of the discontinuation criteria de-
scribed earlier, disease progression, ECOG PS 2, significant
toxicity precluding continuation of CP therapy, grade 2 PH
before the start of bevacizumab treatment, or grade 2 symp-
tomatic central nervous system hemorrhage.
Bevacizumab dose reduction was not permitted because
there is no dose-response relationship for known bevaci-
zumab toxicities. However, bevacizumab treatment interrup-
tion was permitted for subjects who experienced certain AEs:
any grade non-PH; grade 2 bowel obstruction; grade 3
hypertension, proteinuria, left ventricular systolic dysfunc-
tion, or other events considered related to bevacizumab.
Data Analysis and Statistics
Descriptive statistics, including n (%) or median and
range, are presented for demographic and patient character-
istics and discontinuation and treatment characteristics. Inci-
dence of select AEs is presented for the safety-evaluable
population that included patients who received at least one
dose of bevacizumab. For incidence of grade 3 PH, 90%
confidence intervals (CI) were estimated using the Blyth-
Still-Casella exact method.
The efficacy population consisted of all subjects who
received at least one dose of bevacizumab. PFS was defined as
the time from enrollment to documented disease progression
based on RECIST criteria (investigator assessment) or death.
Kaplan–Meier methodology was used to characterize the distribu-
tion of PFS and to estimate the probability of PFS of 6 months.
RESULTS
Study Population
From April 2006 to April 2008, 47 patients were
enrolled in the study and received CP chemotherapy. Of these
47 patients, 31 met the protocol-specified eligibility criteria
and received bevacizumab after two cycles of chemotherapy.
These 31 patients had not experienced disease progression or
exclusionary toxicities (including PH). The other 16 patients
did not proceed to receive bevacizumab for the following
reasons: progression (n  5), AEs (n  6), patient decision
(n  2), or other reasons (n  3) (data not shown).
Approximately two thirds of the patients (31) who went
on to receive bevacizumab were male (Table 1). No patients
with ECOG PS 2 or treated brain metastases received bev-
acizumab in this study. Eighty-one percent of the 31 patients
had stage IV disease; 13% had recurrent disease. Seven
patients (23%) had received prior radiotherapy (four to the
lung and one to the mediastinum); 26% had a prior thoracic
surgery.
TABLE 1. Demographics and Baseline Characteristicsa
Characteristics
Bevacizumab Treated
(n  31)
Age (yr)
Mean (SD) 65.0 (7.9)
Median 65.0
Range 48–80
Age category, yr (%)
65 14 (45.2)
65 17 (54.8)
Sex, n (%)
Male 21 (67.7)
Female 10 (32.3)
Race, n (%)
White 30 (96.8)
African American 1 (3.2)
Baseline Eastern Cooperative Oncology
Group performance status, n (%)
0 12 (38.7)
1 19 (61.3)
No. of metastatic sites
Mean (SD) 2.4 (1.1)
Median 2.0
Range 1–5
Patients with brain metastases, n (%)
No 31 (100.0)
Subjects with prior radiotherapy, n (%)
Yes 7 (22.6)
No 24 (77.4)
Site of prior radiotherapy, n (%)
n 7b
Lung 4 (57.1)
Bone 2 (28.6)
Other 1 (14.3)
Mediastinum 1 (14.3)
Subjects with prior thoracic surgery, n (%)
Yes 8 (25.8)
No 23 (74.2)
Subjects with prior adjuvant or neoadjuvant
systemic therapy, n (%)
Yes 3 (9.7)
No 28 (90.3)
Clinical stage, n (%)
IIIb 2 (6.5)
IV 25 (80.6)
Recurrent 4 (12.9)
a Characteristics of patients who received 1 dose of bevacizumab are shown.
b One patient received prior radiotherapy to both “lung” and “other” sites.
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Safety
The estimated incidence of grade 3 PH was 3.2%
(90% CI 0.3–13.5%) among the 31 patients who received 1
dose of bevacizumab (Table 2). A grade 4 event occurred in
a patient who did not have cavitation at baseline or at cycle
3 screening but developed cavitation before cycle 4. The
patient discontinued from the study after a grade 3 PH and
then experienced the grade 4 PH event 10 days later. The
patient subsequently died of progressive disease. In addition,
there was one grade 1 PH (hemoptysis) that occurred in a
patient who had cavitation pre-cycle 3. Therefore, a total of
two patients (6.5%) experienced a PH event of any grade.
However, given the 2006 protocol amendment excluding
patients with cavitation, this patient should not have contin-
ued in the study. No other grade3 bleeding events occurred
in this study. The relationship between timing of prior radio-
therapy and risk of early bleeding, a secondary objective,
could not be addressed in this study. There were no PH events
among the 16 patients who did not receive bevacizumab.
No grade 5 AEs were reported in this study. The most
frequently reported grade 3 events were hypertension
(16.1%), dyspnea (9.7%), deep vein thrombosis (a venous
thromboembolic event; 6.5%), and arthralgia (6.5%; Table 2).
The protocol-specified selected AEs (AEs) of any grade
reported in 5% of safety-evaluable patients included hyper-
tension (19.4%; six patients: 5 patients, grade 3; 1 patient,
grade 2); deep vein thrombosis (6.5%; two patients, grade 3);
and PH (6.5%; two patients: one patient, grade 4; one patient,
grade 1). There were no reports of reversible posterior leu-
koencephalopathy syndrome or hypertensive encephalopathy.
Tumor Characteristics
Independent review facility analysis of radiographic
scans collected at baseline showed an average of 2.7 intratho-
racic lesions per patient (data not shown). Five patients (11%)
had baseline cavitations; two of these patients were discon-
tinued from the study and did not receive any bevacizumab;
the other three patients received 1 dose of bevacizumab
on-study. Eight additional patients had evidence of de novo
cavitation at the pre-cycle 3 screening; three of these patients
did not receive any bevacizumab in the study, and the
remaining five patients received 1 cycle of bevacizumab.
After the pre-cycle 3 scan, new cavitations were observed in
nine of the patients who had received bevacizumab.
Extent of Exposure and Patient Disposition
The median total dose of bevacizumab received was
5730 mg, for a median of six cycles (data not shown). Ten
patients completed six cycles of bevacizumab plus chemo-
therapy and went on to receive single-agent bevacizumab. Of
the 31 patients who received bevacizumab, three had delays
in 1 treatment cycle (21 days).
Of the 31 bevacizumab-treated patients, 52% discon-
tinued bevacizumab because of progressive disease (Table 3).
Ten patients (32.2%) discontinued because of an AE: grade 4
cerebral ischemia, dyspnea, and proteinuria; grade 3 deep
vein thrombosis (in two patients), hypertension, peripheral
neuropathy, and congestive heart failure; grade 2 cerebral
infarction; and grade 1 pulmonary embolism. Nineteen pa-
tients were still alive as of the data cutoff (July 6, 2009).
Twelve patients (38.7%) had bevacizumab treatment inter-
ruptions (median of 14 days).
TABLE 2. Incidence of Grade 3 Adverse Eventsa
Patients with
Grade 3 Events
(n  31)
Patients with
Grade 4 Events
(n  31)
Any grade 3 adverse
events, total, n (%)
14 (45.2) 6 (19.4)
Listing of adverse events,
n (%)
Hypertension 5 (16.1) 0
Dyspnea 2 (6.5) 1 (3.2)
Pulmonary hemorrhage 0 1 (3.2)
Arthralgia 2 (6.5) 0
Deep vein thrombosis 2 (6.5) 0
Basal ganglia infarction 0 1 (3.2)
Cerebral ischemia 0 1 (3.2)
Pain 0 1 (3.2)
Proteinuria 0 1 (3.2)
Asthenia 1 (3.2) 0
Chest pain 1 (3.2) 0
Confusional state 1 (3.2) 0
Congestive heart failure 1 (3.2) 0
Hemoptysisb 1 (3.2) 0
Hip fracture 1 (3.2) 0
Infection 1 (3.2) 0
Peripheral neuropathy 1 (3.2) 0
Pneumonia 1 (3.2) 0
Small bowel obstruction 1 (3.2) 0
a The highest grade of event is reported for each patient.
b This event occurred in the same patient who had grade 4 pulmonary hemorrhage.
TABLE 3. Exposure to Study Treatment and Patient
Disposition
Bevacizumab-Treated
Patients (n  31)
No. of cycles of bevacizumab
Mean (SD) 6.3 (4.6)
Median 6.0
Range 1–18
No. of cycles of chemotherapy
Mean (SD) 5.2 (1.0)
Median 6.0
Range 3–6
Patient disposition, n (%)
Completed 12 mo of bevacizumab treatment 2 (6.5)
Discontinued treatment, total 29 (93.5)
Due to disease progression 16 (51.6)
Due to adverse event 9 (29.0)
Due to patient’s decision 1 (3.2)
Due to other reason 3 (9.7)
Still alive as of study cutoff 19 (61.3)
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Median PFS among the bevacizumab-treated patients
(n  31) was 6.2 months (95% CI 5.32–7.62 months).
Approximately 57% of bevacizumab-treated subjects had
PFS of 6 months or more.
DISCUSSION
The BRIDGE study was designed to explore whether
the risk of PH would be reduced in patients with squamous
NSCLC by delaying the start of bevacizumab treatment (by
two cycles) and by excluding patients with baseline risk
factors for PH, including baseline cavitation, tumor impinge-
ment or extension into major blood vessels, history of he-
moptysis or significant vascular disease, or evidence of bleed-
ing diathesis or coagulopathy. Many of these risk factors
were first identified in the phase II trial of bevacizumab for
NSCLC (AVF0757g).2,4 Delayed administration of bevaci-
zumab was based on the hypothesis that this may permit
cytoreduction and epithelial healing. This study had the
largest sample size of bevacizumab-treated patients with
squamous NSCLC to date.
The estimated incidence of grade 3 PH (3.2%, 90%
CI 0.3–13.5%, one patient) in this study was less than
expected based on prior experience (31% of patients with
squamous NSCLC in AVF0757g),2–4 and was acceptable as
defined by the study protocol (up to 2 grade3 events among
30 bevacizumab-treated patients). The patient with grade
3 PH did not have baseline or pre-cycle 3 evidence of
cavitation but developed cavitation by cycle 4. PH events of
any grade occurred in two patients (6.5%; grades 1 and 4).
There were no reports of grade3 bleeding events except for
PH. The median PFS in this study (6.2 months, 95% CI
5.32–7.62) is favorable compared with historical data on
first-line chemotherapy for patients with metastatic nonsqua-
mous NSCLC, but interpretation is confounded by issues of
patient selection: radiographically stable or responding dis-
ease after two cycles of CP (favorable), versus predominantly
male population and preponderance of cigarette smoking in a
population of patients with squamous histology (unfavor-
able), and the small number of patients in this study. Al-
though the results from this study are encouraging compared
with prior experience, this small single-arm study was not
designed to directly address whether delaying the adminis-
tration of bevacizumab by two cycles and selecting subjects
without baseline risk factors reduced the risk of PH or
improved the efficacy of CP. This would require a random-
ized design. Overall, the results of this study suggested an
acceptable risk to benefit ratio in the setting of delayed
bevacizumab administration.
A retrospective assessment of CT scans for features
associated with PH concluded that cavitation and baseline
hemoptysis were potential risk factors for PH in the setting of
nonsquamous and mixed histology NSCLC.4 Squamous his-
tology is more likely to be associated with cavitation in
NSCLC. In the BRIDGE study, there was no evidence of
baseline cavitation in the patient with grade 3 PH. There
was an initial increase in the rate of cavitation development in
patients precycle 3 (chemotherapy alone). The number and
size of cavitated lesions did not seem to increase after cycle
3; however, the small number of patients in this study does
not permit conclusions to be made. Eligibility criteria in other
studies of bevacizumab for NSCLC treatment have excluded
patients with NSCLC of predominantly squamous histology;
however, patients with mixed histologies that are composed
primarily of nonsquamous elements have received bevaci-
zumab in these other studies.
A recent European study (BO19734, AVASQ) assessed
the safety of treatment with cisplatin-gemcitabine or CP with
the addition of bevacizumab from cycle 2 onward in patients
with advanced squamous NSCLC who were at risk for
development of PH (defined as patients presenting with
central tumors of any size or peripheral tumors with longest
diameter 2 cm that had not been irradiated previously). All
patients received a short course of radiation therapy 3 weeks
before starting chemotherapy. Patients who had experienced
grade 2 hemoptysis up to 3 months before study entry were
not eligible. Among the first 20 patients to receive bevaci-
zumab, two (10%, 90% CI 2.7–25.9) experienced grade 3
PH events: a grade 3 and a grade 5 event (in a patient who
was found after central review to have tumor involvement in
major blood vessels). The study was terminated early.
It is unclear whether factors at the molecular level
should be considered in the treatment of squamous versus
nonsquamous NSCLC. Although histology has not been tra-
ditionally considered among the prognostic factors associated
with survival in the setting of NSCLC,9,10 a phase III trial
recently showed that pemetrexed plus cisplatin had lower
efficacy against squamous NSCLC than gemcitabine plus
cisplatin, whereas pemetrexed and cisplatin had greater effi-
cacy against adenocarcinoma NSCLC.11–13 Squamous cell
carcinoma had no correlative associations with KRAS or
EGFR mutations in NSCLC.14,15 These findings underscore
the need to discover biomarkers associated with predictive or
prognostic value for squamous NSCLC.
There is an ongoing need to assess therapies that may
improve survival in metastatic squamous NSCLC. Other
drugs that are undergoing assessment in clinical trials for
squamous NSCLC include monoclonal antibodies against the
insulin-like growth factor type I receptor (figitumumab,16
AMG-479,17 and MK064618) and axitinib, a small molecule
inhibitor of vascular endothelial growth factor receptors 1, 2,
and 3.19 However, two recent trials involving patients with
squamous cell carcinoma of the lung were either terminated
early (CP-751,871, an insulin-like growth factor type 1 in-
hibitor) or resumed with only nonsquamous patients (mote-
sanib, a multitargeted tyrosine kinase inhibitor). Bevaci-
zumab was shown to be well tolerated in two studies in other
cancers of squamous histology (squamous cancer of the head
and neck20–22 and squamous esophageal cancer23) with en-
couraging response rates.
In conclusion, the BRIDGE study, in which the start
of bevacizumab treatment was delayed and in which pa-
tients with baseline risk factors for PH were excluded,
showed a lower rate of grade 3 PH (1/31 [3.2%] patients,
90% CI 0.3–13.5%) than was observed in an earlier phase
II study including patients with squamous NSCLC. Al-
though the observed rate of PH was low, this was a small
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study (31 patients received bevacizumab), and treatment of
squamous NSCLC with bevacizumab should be considered
experimental.
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